Vall d'Hebron Talks by VHIR 'Development of Advanced Drug Delivery Systems for the Systemic and Local Treatment of Challenging Diseases'

 Vall d'Hebron Talks by VHIR
  Sala d’actes de la planta baixa de l'edifici Collserola del VHIR — See in map
13/12/2023 -- From 12:00h to 13:00h
Organize :
Vall d'Hebron Institut de Recerca (VHIR)
Modality: Presencial
Share it:

Speaker; Dr. Diana Rafael, main researcher Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT) VHIR

Abstract: The constant development of new synthetic drug delivery systems in the last years have been highly contributing to the advancement of new treatments for a wide-range of challenging diseases, for which the conventional treatments are not efficient. The use of nanoparticles and hydrogels have been a breakthrough in clinical application, with hundreds of new products enrolling clinical trials and being approved in the clinical practice.
In the CB-DDT group we are experts in the development of new therapeutic strategies based on nanoparticles and hydrogels for several different clinical applications. This presentation will be divided in two parts: The first one dedicated to the most promising works regarding the development of nanoparticles encapsulating different drugs and biomolecules for the systemic treatment of different pathological conditions, and the second one dedicated to the most promising results regarding the use of biodegradable, smart hydrogels for cancer local treatment.

Bio Sketch: Diana Rafael, is a Principal Investigator at VHIR. She has a PhD in Pharmaceutical Technology (2017), and since 2013 she has been associated with the Clinical Biochemistry: Drug Delivery and Therapy Group from VHIR, where she initiated a research line dedicated to the production and characterization of Delivery Systems. Diana participated in more than 12 highly competitive national and international research projects and her research work originated 2 patents and more than 40 peer-reviewed publications. This year, Diana was granted with a Global Marie Sk³odowska-Curie Postdoctoral Fellowship and a Grant from the Spanish Association against the Pancreatic Cancer. Moreover, since January Diana has been implementing a new section within the FVPR/U20 platform of the Nanbiosis, certified by ISO9001:2015, dedicated to the synthesis and characterization of Nanosystems. 

Host: Dr. Ibane Abasolo, head of group Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT) VHIR

Related activities

I Jornada d’abordatge clínic en malalties infeccioses

04/17/2024 - 16:00
Dirigit a residents de qualsevol especialitat.
More information

Curso de introducción a la metodología estadística en investigación en salud

04/22/2024 - 09:00
El curso de Introducción a la Metodología Estadística en Investigación en Salud está dirigido a personas que quieren empezar a investigar en el ámbito de las ciencias de la salud y tienen conocimientos básicos previos en estadística.
More information

III Curso TEA a lo largo de la vida

04/25/2024 - 09:00
Psiquiatras, psicólogos y cualquier profesional vinculado a la salud mental.
More information

Vacunas 2024 - XXVIII Curso de Actualización en Inmunizaciones (presencial y virtual)

04/25/2024 - 09:00
More information

Subscribe to our newsletters and be a part of Campus Life

Select the newsletter you want to receive:

By accepting these conditions, you are agreeing to the processing of your personal data for the provision of the services requested through this portal, and, if necessary, for any procedures required by the administrations or public bodies involved in this processing, and their subsequent inclusion in the aforementioned automated file. You may exercise your rights to access, rectification, cancellation or opposition by writing to, clearly stating the subject as "Exercising of Data Protection Rights".
Operated by: Hospital Universitari Vall d'Hebron - Institut Català de la Salut.
Purpose: Manage the user’s contact information.
Legitimisation: Express acceptance of the privacy policy.
Rights: To access, rectify, and delete personal information data, as well to the portability thereof and to limit and/or oppose their use.
Source: The interested party themselves.